Question 1

What is ACOU085?

Accepted Answer

ACOU085 is a Other.

Question 2

How often does ACOU085 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was ACOU085 first tracked by Ergen?

Accepted Answer

First tracked on Jun 12, 2026.

Question 4

When was ACOU085 last mentioned in news?

Accepted Answer

Last active on Jun 12, 2026.

Question 5

What is ACOU085's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ACOU085 in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ACOU085?

Accepted Answer

Acousia Therapeutics ACOU085 Phase 2a Results (Jun 12, 2026, 6 articles).

Question 8

How did the "Acousia Therapeutics ACOU085 Phase 2a Results" event impact ACOU085?

Accepted Answer

ACOU085 (Bimokalner) is the drug candidate developed by Acousia Therapeutics GmbH that showed clinically meaningful prevention of hearing loss in the PROHEAR Study.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.